3-Phenyl-2,4-dithioxo-1,2,3,4-tetrahydroquinazoline

ID: ALA1927722

Chembl Id: CHEMBL1927722

Cas Number: 16081-93-9

PubChem CID: 3008080

Max Phase: Preclinical

Molecular Formula: C14H10N2S2

Molecular Weight: 270.38

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  S=c1[nH]c2ccccc2c(=S)n1-c1ccccc1

Standard InChI:  InChI=1S/C14H10N2S2/c17-13-11-8-4-5-9-12(11)15-14(18)16(13)10-6-2-1-3-7-10/h1-9H,(H,15,18)

Standard InChI Key:  DJJOAJCVIYRELX-UHFFFAOYSA-N

Alternative Forms

Associated Targets(Human)

PDE7A Tclin Phosphodiesterase 7A (1104 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDE7A Tclin Phosphodiesterase 7 (77 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 270.38Molecular Weight (Monoisotopic): 270.0285AlogP: 4.42#Rotatable Bonds: 1
Polar Surface Area: 20.72Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 9.83CX Basic pKa: CX LogP: 4.41CX LogD: 4.41
Aromatic Rings: 3Heavy Atoms: 18QED Weighted: 0.66Np Likeness Score: -1.12

References

1. Redondo M, Zarruk JG, Ceballos P, Pérez DI, Pérez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI, Campillo NE, Martínez A, Gil C..  (2012)  Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.,  47  [PMID:22100138] [10.1016/j.ejmech.2011.10.040]
2. Redondo M, Soteras I, Brea J, González-García A, Cadavid MI, Loza MI, Martinez A, Gil C, Campillo NE..  (2013)  Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities.,  70  [PMID:24239625] [10.1016/j.ejmech.2013.10.035]
3. García AM, Brea J, Morales-García JA, Perez DI, González A, Alonso-Gil S, Gracia-Rubio I, Ros-Simó C, Conde S, Cadavid MI, Loza MI, Perez-Castillo A, Valverde O, Martinez A, Gil C..  (2014)  Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.,  57  (20): [PMID:25264825] [10.1021/jm501090m]
4. Haghighijoo Z, Zamani L, Moosavi F, Emami S..  (2022)  Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.,  227  [PMID:34742016] [10.1016/j.ejmech.2021.113949]

Source